GSK notches clinical win with anti-BCMA ADC amid cancer pipeline push

GlaxoSmithKline's return to cancer took another large step forward as one of its most prominent oncology candidates succeeded in a pivotal Phase II trial to treat multiple myeloma.

On Friday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said anti-BCMA antibody-drug conjugate belantamab mafodotin (GSK2857916) met the primary endpoint of overall response

Read the full 476 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE